Cancer Horizons5 Helmi 2020

S3 Ep7: Seven Times Down, Eight Times Up

Although many have never heard of them, pheochromocytoma and paraganglioma are two types of rare cancers that are not news to Matthew Capogreco and his family. With a long list of relatives – nine to be exact – who were diagnosed with these two tumor types, Capogreco himself was 25 when he demanded his physician test him for the disease after feeling symptoms his father had already experienced before his own diagnosis. He was first diagnosed with bi-lateral carotid paragangliomas asymptomatic and has since had multiple bouts of pheochromocytoma and paraganglioma. With this, his motto has turned to “seven times down, eight times up.” “The person that preserveres is the one who gets up that one last time,” Capogreco. “That’s what we have to do. We have no choice. If we’re down at the end and we don’t back up, there’s no coming back from it.” Now cancer free, Capogreco serves as the president of the Board of Pheo Para Alliance, which aims to empower patients with pheochromocytoma or paraganglioma, their families and medical professionals through advocacy, education and a global community of support, while helping to advance research that accelerates treatments and cures. “The question is why should other people care about this rare disease that will never touch your life?” he said. “My response to that is this small disease has so many components we know about…if you could solve one small piece of the cancer puzzle it will have a great effect on all of the other puzzle pieces.” For more information, visit pheopara.org.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(295)

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berg...

31 Joulu 202514min

S7 Ep1: The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

18 Maalis 202510min

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

17 Syys 202419min

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another ca...

4 Maalis 20247min

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, an...

4 Maalis 202410min

S6 Ep20: FDA Approvals from February 2024

Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers. ...

23 Helmi 20246min

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tum...

19 Helmi 20249min

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered researc...

12 Helmi 20247min